Connect Biopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership)(9.6%),Suzhou Xiangtang Venture Investment Limited(9.6%), etc.
康乃德生物 | SC 13G：超過5%持股股東披露文件-Shanghai Minhui Enterprise Management Consulting Partnership (Limited Partnership)(9.6%),Suzhou Xiangtang Venture Investment Limited(9.6%)等
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。